Carbonation and Sweet Taste Dysgeusia with Topiramate Therapy for Migraine Prevention Treatment: a Case Report
Abstract
Migraine is a common disorder with a reported prevalence of up to 12% in the European general population. It has been shown to cause a reduction in quality of life with symptoms that range from headaches, nausea, and vomiting to external stimuli hypersensibility. Migraine preventive treatment identifies numerous medication groups including anticonvulsants such as topiramate. We report the first case of carbonated and sweet taste dysgeusia during topiramate treatment for migraine prevention. We present the case of a 30-year-old man with a 6-month history of headache with aura associated with nausea, vomiting, photophobia, and blurred vision. A preventive migraine therapy with topiramate was started. After 4 weeks, the patient developed carbonation and sweet taste dysgeusia determining a major impact on quality of life and low therapy adherence. To improve patient’s quality of life, we attempted to switch therapy from topiramate to sodium valproate, but his noncompliant behavior imposed us to continue the current therapy. Thus, the patient was sent for a psychological evaluation and counseling eventually accepting to continue therapy. To date, no reports have been published in the literature on coexistent carbonation and sweet taste dysgeusia linked to topiramate migraine preventive therapy. We hypothesize that topiramate, modulating GABAergic transmission, could influence sweet taste transmission at the taste bud level in an already modulated taste receptor environment.…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.